Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Ploner, F; Lamm, W; Schur, S; Eisterer, W; Kühr, T; Lindorfer, A; Tinchon, C; Köstler, WJ; Szkandera, J; Brodowicz, T.
The Austrian experience with trabectedin in non-selected patients with metastatic soft tissue sarcoma (STS).
J Cancer Res Clin Oncol. 2013; 139(8):1337-1342
Doi: 10.1007/s00432-013-1447-8
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Ploner Ferdinand
- Co-authors Med Uni Graz
- Szkandera Joanna
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The purpose of this retrospective analysis was to assess efficacy and tolerability of trabectedin in soft tissue sarcoma (STS) in the routine clinical setting. Efficacy and safety data of trabectedin were retrospectively evaluated in patients with advanced STS who had started treatment with trabectedin at six institutions in Austria between January 2008 and May 2012. Data of 101 adult patients were included in the present analysis. Patients had a median age of 56 years; 59 and 41 % received trabectedin as a parts per thousand currency sign2nd and a parts per thousand yen3rd chemotherapy line for advanced disease, respectively. Median progression-free survival (PFS) and overall survival (OS) were 3.9 and 11.6 months. Median PFS and OS were different in patients who received trabectedin as a parts per thousand currency sign2nd- or a parts per thousand yen3rd-line treatment: median PFS was 3.9 versus 3.6 months and OS was 15.2 versus 24.8 months, respectively. The extent and severity of trabectedin-induced toxicity were low and manageable. The activity and tolerability of trabectedin in the routine clinical setting is comparable to outcomes reported in phase II trials already published. Regardless of whether trabectedin was given earlier or later in the course of disease, outcomes did not differ in the cohort of analysed patients.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Aged, 80 and over -
- Antineoplastic Agents, Alkylating - therapeutic use
- Antineoplastic Agents, Alkylating -
- Dioxoles - therapeutic use
- Disease-Free Survival -
- Female -
- Humans -
- Kaplan-Meier Estimate -
- Male -
- Middle Aged -
- Retrospective Studies -
- Sarcoma - drug therapy Sarcoma - mortality
- Soft Tissue Neoplasms - drug therapy Soft Tissue Neoplasms - mortality
- Tetrahydroisoquinolines - therapeutic use
- Treatment Outcome -
- Young Adult -
- Find related publications in this database (Keywords)
- Soft tissue sarcoma
- Metastatic
- Trabectedin